Modulation of tissue glucocorticoid exposure by cleavage of corticosteroid binding globulin in humans
dc.contributor.advisor
Walker, Brian
dc.contributor.advisor
Nixon, Mark
dc.contributor.advisor
Stimson, Roland
dc.contributor.author
Boyle, Luke David
dc.contributor.sponsor
Wellcome Trust
en
dc.date.accessioned
2024-05-02T15:04:18Z
dc.date.available
2024-05-02T15:04:18Z
dc.date.issued
2024-05-02
dc.description.abstract
Corticosteroid Binding Globulin (CBG) binds over 85% of plasma cortisol and modulates free
cortisol levels. Observations in vitro show that CBG undergoes proteolytic cleavage by
neutrophil elastase (NE) at its reactive centre loop (RCL), a mechanism proposed to reduce
CBG binding capacity by approximately ten-fold and increase the availability of free cortisol
to tissues at sites of inflammation. However, detection of cleaved CBG in vivo in human
plasma is controversial, and any influence of NE on CBG cleavage has not been tested in vivo.
The CORtisol NETwork (CORNET) consortium found that genetic variation at a locus spanning
SERPINA1 (encoding alpha-1 antitrypsin, AAT, the endogenous inhibitor of NE) and SERPINA6
(CBG) contributes to morning total plasma cortisol variation.
We tested the hypotheses that: (i) CBG cleavage occurs in tissues in vivo, controlling tissue
cortisol delivery; (ii) AAT deficiency increases CBG cleavage and hence free plasma cortisol;
(iii) greater cleavage of CBG results in increased tissue cortisol delivery in adipose and in
hypothalamic-pituitary-adrenal (HPA) axis negative feedback; and (iv) NE inhibition inhibits
NE-mediated CBG cleavage and thus plasma free cortisol in vivo.
To test tissue-specific CBG cleavage we recruited 48 men and collected arterialised blood and
samples from veins draining abdominal subcutaneous adipose, forearm skeletal muscle, brain
and liver. Arterio-venous differences in CBG were calculated, adjusting for blood flow. Net
CBG production from the liver was detected in people with obesity and type 2 diabetes, but
no in vivo cleavage of CBG was observed across the tissues studied.
In recall-by-genotype studies of people who are heterozygous for inactivating mutations in
SERPINA1, 16 healthy carriers of either of the two most common AAT-deficiency single
nucleotide polymorphisms (rs17580 & rs28929474) and 16 age-, sex- and BMI-matched
controls were recruited from the Generation Scotland Biobank. Participants underwent
placebo-controlled combined receptor antagonist stimulation of the HPA axis (‘CRASH’)
testing using the glucocorticoid receptor antagonist RU486 plus mineralocorticoid receptor
antagonist spironolactone, in a double-blind randomised crossover design. No measurable
differences in CBG were observed. However, plasma free cortisol fraction was higher in those
carrying AAT mutations. Adipose cortisol concentrations were not significantly different but
transcripts of glucocorticoid-responsive genes were higher in adipose from AAT-deficient
subjects. Plasma cortisol was elevated during CRASH testing in both groups, with the
increment versus placebo tending to be lower in AAT-deficient subjects.
Using coronary artery bypass graft (CABG) surgery as a model of acute neutrophil-mediated
inflammation, we measured CBG and cortisol in a randomised double-blind parallel group
clinical trial of 35 patients administered placebo or elafin, an endogenous NE inhibitor,
intravenously immediately before CABG surgery. Plasma CBG concentration and binding
capacity fell by >30% following surgery, with corresponding increases in total and free
cortisol, with a trend towards higher, rather than lower free cortisol in the elafin-treated
group.
In conclusion, these data suggest that AAT deficiency brings about changes consistent with
enhanced cleavage of CBG, including enhanced delivery of glucocorticoid to adipose tissue
and reduced tonic HPA axis negative feedback. This is consistent with a role for intact CBG in
delivery of cortisol to the central HPA axis and a role for CBG cleavage in releasing cortisol to
enhance tissue access in inflamed adipose tissue.
en
dc.identifier.uri
https://hdl.handle.net/1842/41732
dc.identifier.uri
http://dx.doi.org/10.7488/era/4455
dc.language.iso
en
en
dc.publisher
The University of Edinburgh
en
dc.relation.hasversion
Hill LA, Vassiliada DA, Dimopoulou I, Anderson AJ, Boyle LD, Kilgour AHM, Stimson RH, Machado Y, Overall CM, Walker BR, Lewis JG, Hammond GL. Neutrophil elastase-cleaved corticosteroid-binding globulin is absent in human plasma. J Endocrinol. 2019 Jan 1;240(1):27- 39. PMID: 30452386
en
dc.relation.hasversion
Anderson, A.J., Andrew, R., Homer, N.Z.M., Hughes, K.A., Boyle, L.D., Nixon, M., Karpe, F., Stimson, R.H., and Walker, B.R. (2020). Effects of Obesity and Insulin on Tissue-Specific Recycling Between Cortisol and Cortisone in Men. The Journal of Clinical Endocrinology & Metabolism 106, e1206-e1220.
en
dc.relation.hasversion
Hill, L.A., Vassiliadi, D.A., Dimopoulou, I., Anderson, A.J., Boyle, L.D., Kilgour, A.H.M., Stimson, R.H., Machado, Y., Overall, C.M., Walker, B.R., et al. (2019b). Neutrophil elastase cleaved corticosteroid-binding globulin is absent in human plasma. J Endocrinol 240, 27-39
en
dc.subject
cortisol
en
dc.subject
cortisol levels
en
dc.subject
Corticosteroid Binding Globulin
en
dc.subject
CBG
en
dc.subject
human neutrophil elastase
en
dc.subject
Alpha-1 Antitrypsin
en
dc.subject
inflammation
en
dc.title
Modulation of tissue glucocorticoid exposure by cleavage of corticosteroid binding globulin in humans
en
dc.type
Thesis or Dissertation
en
dc.type.qualificationlevel
Doctoral
en
dc.type.qualificationname
PhD Doctor of Philosophy
en
Files
Original bundle
1 - 1 of 1
- Name:
- Boyle2024.pdf
- Size:
- 3.58 MB
- Format:
- Adobe Portable Document Format
- Description:
This item appears in the following Collection(s)

